FDA Approves Groundbreaking Drug That Slows Pancreatic Cancer
The FDA approved Rasonque, the brand name for Daraxonrasib, for late-stage pancreatic cancer patients who haven't responded to prior treatments, like chemotherapy The drug targets the KRAS protein and has been shown to double survival time compared to chemotherapy alone Former Sen.